anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
BACKGROUND AND OBJECTIVE: Atrial Fibrillation (AF) is a supraventricular tachyarrhythmia that can lead to thromboembolism, hearlt failure, ischemic stroke, and a decreased quality of life. Characterizing the locations where the mechanisms of AF are initialized and maintained is key to accomplishing an effective ablation of the targets, hence restoring sinus rhythm. Many methods have been investigated to locate such targets in a non-invasive way, such as Electrocardiographic Imaging, which enables an on-invasive and panoramic characterization of cardiac electrical activity using recording Body Surface Potentials (BSP) and a torso model of the patient. Nonetheless, this technique entails some major issues stemming from solving the inverse problem, which is known to be severely ill-posed. In this context, many machine learning and deep learning approaches aim to tackle the characterization and classification of AF targets to improve AF diagnosis and treatment.
METHODS: In this work, we propose a method to locate AF drivers as a supervised classification problem. We employed a hybrid form of the convolutional-recurrent network which enables feature extraction and sequential data modeling utilizing labeled realistic computerized AF models. Thus, we used 16 AF electrograms, 1 atrium, and 10 torso geometries to compute the forward problem. Previously, the AF models were labeled by assigning each sample of the signals a region from the atria from 0 (no driver) to 7, according to the spatial location of the AF driver. The resulting 160 BSP signals, which resemble a 64-lead vest recording, are preprocessed and then introduced into the network following a 4-fold cross-validation in batches of 50 samples.
RESULTS: The results show a mean accuracy of 74.75% among the 4 folds, with a better performance in detecting sinus rhythm, and drivers near the left superior pulmonary vein (R1), and right superior pulmonary vein (R3) whose mean sensitivity bounds around 84%-87%. Significantly good results are obtained in mean sensitivity (87%) and specificity (83%) in R1.
CONCLUSIONS: Good results in R1 are highly convenient since AF drivers are commonly found in this area: the left atrial appendage, as suggested in some previous studies. These promising results indicate that using CNN-LSTM networks could lead to new strategies exploiting temporal correlations to address this challenge effectively.
On the basis of baseline medication, high-dose fecal microbiota transplantation (FMT) will be administered, with subjects taking 50 fecal microbiota capsules. Subsequently, maintenance doses will be administered at week 2, 4, 8, 12, and 20, with 10 capsules taken each time. Fasting is required 4 hours before and 1 hour after capsule ingestion, and subjects are instructed to maintain a stable diet and physical activity pattern throughout the 24-week study period. Capsules will be transported on ice and warmed for 10 minutes at 37°C before FMT administration.
The invention relates to marsupenaeus japonicus thymulin genes, and a preparation method and applications of marsupenaeus japonicus thymulins, and relates to nucleotide sequences of the marsupenaeus japonicus thymulin genes, and amino acid sequences encoded by the nucleotide sequences. The marsupenaeus japonicus thymulin genes comprise a marsupenaeus japonicus thymulin mjthm4 gene, a marsupenaeus japonicus thymulin mjthm3 gene and a marsupenaeus japonicus thymulin mjthm2 gene. The preparation method comprises a step of extracting total RNA of marsupenaeus japonicus; a step of performing inverse transcription for marsupenaeus japonicus cDNA; a step of performing PCR amplification and sequence analysis for the marsupenaeus japonicus thymulin genes; and a step of recombining and expressing the marsupenaeus japonicus thymulins. The marsupenaeus japonicus thymulins can be used for preparing anti-prawn-virus medicines. Through homologous recombination and expression of the three thymulins, deficiencies, namely complex and tedious processes, low yield, etc. of separation and purification are overcame, thus laying the foundations of applications of the proteins in the research fields of biology, food, medicine, agriculture, and the like.
Deaf and hard-of-hearing people mainly communicate using sign language, which is a set of signs made using hand gestures combined with facial expressions to make meaningful and complete sentences. The problem that faces deaf and hard-of-hearing people is the lack of automatic tools that translate sign languages into written or spoken text, which has led to a communication gap between them and their communities. Most state-of-the-art vision-based sign language recognition approaches focus on translating non-Arabic sign languages, with few targeting the Arabic Sign Language (ArSL) and even fewer targeting the Saudi Sign Language (SSL). This paper proposes a mobile application that helps deaf and hard-of-hearing people in Saudi Arabia to communicate efficiently with their communities. The prototype is an Android-based mobile application that applies deep learning techniques to translate isolated SSL to text and audio and includes unique features that are not available in other related applications targeting ArSL. The proposed approach, when evaluated on a comprehensive dataset, has demonstrated its effectiveness by outperforming several state-of-the-art approaches and producing results that are comparable to these approaches. Moreover, testing the prototype on several deaf and hard-of-hearing users, in addition to hearing users, proved its usefulness. In the future, we aim to improve the accuracy of the model and enrich the application with more features.
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.

Experience with BabyBIG. No adverse reactions have been identified or reported that are ascribed to the use of BabyBIGduring postapproval use. Retrospective publications have shown safety-related information consistent with the safety-related information in the approved product labeling, and no new safety-related information has been presented for BabyBIG.[19, 20]

Experience with Other IGIV Products. Some classes of adverse reactions that have not been reported in BabyBIG clinical studies or postmarketing experience have been observed with the overall post-approval use of other IGIV products, as shown in the following table.
INTRODUCTION: It is widely acknowledged that good hand hygiene (HH) is an important non-pharmaceutical method for reducing the transmission of infectious diseases. Children are at high risk of infection due to their immature immune systems. Hospital transmitted infections are a cause for concern worldwide, with poor HH suggested to be responsible for up to 20% of cases. Patients, in particular paediatric patients, are often overlooked when it comes to the promotion of hand hygiene compliance (HHC) in hospitals. This report describes the clinical evaluation of the 'Soaper Stars'; a collection of child-friendly HH products with linked educational resource, developed using the COM-B approach to behaviour change, and designed to encourage correct HH in paediatric patients and in schools.
METHOD: The Soaper Star products were distributed on paediatric wards in five UK hospitals, and the use of the products around mealtimes was evaluated. Workshops teaching the 'why when and how' of handwashing were run in four UK primary schools with pre and post evaluations conducted to establish impact on knowledge. Over 300 children were involved.
RESULTS: The Soaper Stars products stimulated a 38% increase in HHC compared to when only hospital-issued products were available, and verbal feedback from families indicated that having the Soaper Star products encouraged improved HHC by all visitors, not just the patient. Workshops in four schools (283 pupils) showed an increase in knowledge around the transmission of infection and the need for good HH that was sustained for at least 4 weeks.
CONCLUSION: The results of this study demonstrate that providing children with the age-appropriate knowledge about why HH is necessary, and the child-friendly means to maintain their HH, will lead to greater HHC, not just by individual children, but also their families.
This is an open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), and multi-center (conducted in more than one center) study of abiraterone in male participants with prostate cancer. The duration of study will be approximately 24-32 weeks per participant. The study consists of 4 parts: Screening (that is, 30 days before study commences on Day 1); Treatment (abiraterone acetate 1000 milligram per day or leuprolide acetate as 22.5 milligram intramuscular injection \[injection of a substance into a muscle\] or prednisone 5 mg once daily); Prostatectomy (Week 24); and Follow-up ( 4-8 weeks after prostatectomy). Participants will receive either abiraterone, leuprolide and prednisone for 24 weeks (that is, Group 1) or leuprolide once every 12 weeks up to Week 24 then abiraterone and prednisone from Week 13 to 24 (that is, Group 2). All the eligible participants will be randomly assigned to 1 of the 2 treatment groups. Efficacy will be evaluated primarily through the concentrations of testosterone and dihydrotestosterone from prostate tissues at Week 12. Participants' safety will be monitored throughout the study.
The invention discloses application of pollen pini, a pollen pini extract and a medicinal composition comprising the pollen pini extract in treating the inflammatory bowel disease and a method for preparing the medicinal composition comprising the pollen pini extract. In the preparation method, the pollen pini is extracted by using water, alcohol or a mixture of water and alcohol. Preferably, the alcohol comprises methanol and ethanol, and the concentration of the alcohol is preferably between 40 and 99 percent, and is further preferably 80 percent. During extraction, solvent amount is 5 to 15 times (volume/weight, ml/g) of the weight of an original medicament, and is preferably 10 times in volume. An extraction temperature is between room temperature (such as 20 DEG C) and a solvent reflux temperature, and is preferably a reflux temperature. The extraction can be repeated for 1 to 4 times, each time for 0.5 to 2 hours, preferably for 1 hour. After a previous step is completed, filtrate is combined, dregs of a decoction are filtered and concentrating under reduced pressure, evaporating to dryness or spray drying processes are performed to obtain the pollen pini extract.
The invention relates to a medicine suitable for hemorrhagic early shock. The medicine has an obvious effect mainly aiming at hemorrhagic early shock. The medicine which conforms to the scientific law and has good taste is processed through compatibility of monarch, minister, assistant and guide of crude medicines according to the modern scientific research and reasonable screening. The medicine is prepared by grinding rhizoma curculiginis, small centipeda and tamariskoid spikemoss herb into powder and mixing the powder. The aim of treating hemorrhagic early shock is to improve blood perfusion of the tissues all over the body and recover and maintain the normal metabolism and viscera organ functions of patients but not to simply increase the blood pressure. The medicine is simple and has an obvious effect.
A method for production of rhPBGD in high scale and use of rhPBGD in a method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway. The method comprising administering, to the subject, an effective amount of one or more catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof prefreable in combination with a gene therapy of a mutation related to the catalyst. The disease is selected from the group consisting of acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP). The catalyst is one or more enzymes selected from the group consisting of delta-aminolevulininic acid synthetase, delta-aminovulinic acid dehydratase (ALAD), porphobilinogen deaminase (PBGD), uroporphyrinogen III cosythetase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen oxidase, and ferrochelatase, or an enzymatically equivalent part or analogue therof. In addition the invention relates to the use of rhPBGD. The invention also relates to an expression plasmid pExp1-M2-BB (seq. ID No.1) and to use of a DNA fragment, the EcoR I - Hind III linear fragment (seq. ID No. 2), used for transformation in the hemC disruption strategy for production of rhPBGD expressed in E. coli..
<P>PROBLEM TO BE SOLVED: To provide live or modified live PRRS vaccine for administration to swine which is of low virulence and gives effective immunity against PRRS.  <P>SOLUTION: A preferred vaccine includes virus isolate having average plaque diameter of less than about 2 mm and low pathogenicity. A preferred vaccine includes a small plaque diameter strain, ATCC Accession No. VR2509. The vaccines according to the invention may be administered to breeding sow or boar and to weaned piglets, and is effective to immunize the swine against both the respiratory and reproductive forms of the disease.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m\^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.
Cardiovascular diseases (CVD) are the main cause of death in the European Union. A large part of the aging process, including immunosenescence, is explained by an imbalance between inflammatory and anti-inflammatory networks, wich results in the low grade chronic pro-inflammatory status termed inflammaging. It can contribute to a number of age-related chronic diseases (e.g. atherosclerosis, type 2 diabetes, Alzheimer disease, osteoporosis). Prevention or delay in onset of chronic diseases can potentially benefit a large segment of the elderly population. Now it is hypothesised that a probiotic drink can reduce low-grade inflammation through improvement of the gut barrier function and gut microbiota composition in elderly people with low-grade inflammation.
Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
As part of our growing clinical tracking EMR system the investigators plan to collect preoperative and postoperative Patient Reported Outcome Measures (PROMS) on all patients with degenerative hip and knee disease. The investigators will collect PROMS along with implant device specific revision rates. This will be used for implant surveillance, clinical outcome tracking, return to work outcome metrics and failure modes and rates of various hip and knee implants. Information generated during regular hospital and clinic visits will be entered into the database. For example, x-ray findings done before surgery will be entered into the database. Surgery information will be entered into the database. The investigators will also enter demographic information into the database such as name, email, birthdate, gender, height, and weight. Medical co-morbidities such as diabetes, high blood pressure, and prior surgeries will also be entered.

The investigators will collect this information before surgery, during the operation, and at annual follow-up visits. The investigators will also contact patients via email with short outcome score surveys (known as Patient Reported Outcome Measures or PROM's). This will save many hours of return visits if scores indicate the joint replacements are doing well. Also this will trigger additional follow-up measures if PROMS scores drop off.
PURPOSE: An antifungal composition containing tomato liquid which is prepared by fermenting tomato with bacteria which cause soft rot, and a use thereof are provided to ensure excellent antifungal effect. CONSTITUTION: An antifungal composition contains tomato liquid which is prepared by fermenting tomato with bacteria which cause soft rot, as an active ingredient. The bacteria belong to Pectobacterium species. A method for preventing fungi comprises a step of treating the fungi with the composition. The fungi are candida including C. albicans and C. glabrata. A therapeutic agent for athlete's foot contains the tomato liquid as an active ingredient.
The invention relates to a pharmaceutical formulation in colloidal form for topical application, for the therapy and prophylaxis of pathological changes of the skin and/or cutaneous appendages and/or mucous membranes, including mucous membranes of the intestinal tract, urogenital tract, the bronchial system and/or conjunctiva. Said preparation comprises a lipophilic phase in an amount of 1-10 wt. %, a mixture of surfactant and co-surfactant in an amount of 1-50 wt. %, a hydrophilic phase in an amount of 40-80 wt. % and cyclosporin or derivatives thereof as active ingredient at a concentration of 0.1-20 wt. %.
Participants will receive JNJ-80038114. The dose levels will be escalated based on the dose limiting toxicities (DLTs) evaluation by the study evaluation team (SET).
Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
The invention provides a Chinese medicine combination for curing leukemia and a preparation and application thereof. The combination is prepared from the following ingredients in a proper ratio: hedyotic diffusa, indigo, prepared rhizome of rehmannia, eclipta alba, drynaria rhizome, dogwood, atratylodes rhizome, Chinese magnoliavine fruit, ginseng, astragalus, angelica, donkey-hide gelatin, rheum officinale, pseudo-ginseng, curcuma zedoary, earthworm, cortex moutan, radix bupleuri, turtle shell and oyster. The drug which is prepared from the combination has accurate curative effects. The raw materials are common Chinese medicines which are safe and effective. Both the hemogram and the symptom of early and middle leukemia patients taking the drug for about ten days can be improved, the disease is controlled after one to three months, the leukemia is cured after half a year to one year more or less, and relapse cannot occur after the drug is stopped. The hemogram of late patients can also be improved and stabilized, complications are alleviated or eliminated, pain is relieved, life quality is improved, and the life is prolonged.
The invention discloses a drug double layer core osmotic pump tablet and the preparation method. The drug or the solid dispersion of the drug is mixed uniformly with penetrating agent, thickener and filler, added with adhesive to produce soft material and granulation, baked, and added with lubricant, and then drug layer core tablet material is produced. The penetrating agent, expansive agent and the filler are mixed uniformly, are added with adhesive to produce soft material and particles, are baked and are added with lubricant, and then promoting layer core tablet material is produced. The drug layer core tablet material and the promoting layer core tablet material are punched by a preforming machine with a needle punch to produce double layer core tablet of drug layer with concave holes. Coating liquid containing semi-permeable polymer changes the double layer core tablet of drug layer with concave holes into coated tablet in the coating pot, which is baked to produce double layer core osmotic pump tablet. The double layer core osmotic pump tablet prepared by the invention is similar to zero level release drugs. The invention disuses the slotting process after coating in preparing double layer core osmotic pump tablets without resorting to expensive laser drilling machine, simplifies the preparation process, reduces the cost and fits for industrial production.
Nimodipine is a dihydropyridine calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood-brain barrier; concentrations of nimodipine as high as 12.5 ng/mL have been detected in the cerebrospinal fluid of nimodipine-treated SAH patients.

The precise mechanism of action of nimodipine in reducing the incidence and severity of ischemic deficits in adult patients with SAH from ruptured intracranial berry aneurysms is unknown. Although the clinical studies demonstrate a favorable effect of nimodipine on the severity of neurological deficits caused by cerebral vasospasm following SAH, there is no arteriographic evidence that nimodipine either prevents or relieves the spasm of these arteries. However, whether or not the arteriographic methodology utilized was adequate to detect a clinically meaningful effect, if any, on vasospasm is unknown.